Table 4. Lists of identified drugs targeting upregulated mRNAs with fold change and network degree both greater than two.
| mRNA | Symbol | Fold change | Adjusted p-value | Network degree | Drugs |
|---|---|---|---|---|---|
| Spleen tyrosine kinase | SYK | 2.2 | 0.004 | 7 | Fostamatinib |
| R343 | |||||
| Stromal cell-derived factor 1 | CXCL12 | 3.8 | 0.014 | 3 | Tinzaparin |
| Tyrosine-protein phosphatase non-receptor type 6 | PTPN6 | 2.2 | 0.007 | 2 | Sodium stibogluconate |
| S100 calcium binding protein A4 | S100A4 | 2.2 | 0.006 | 2 | Trifluoperazine |
| Transforming growth factor, beta 1 | TGFB1 | 3.6 | 0.028 | 1 | Hyaluronidase Fresolimumab |
Transforming growth factor, beta 1 is also included for comparison. The network degree refers to number of connections in the full mRNA/microRNA network. The adjusted p-value is the Benjamini-Hochberg adjusted p-value for the t-test for differential mRNA expression between diseased and control aortic valves.